PerkinElmer (NYSE:PKI) announced today that it launched a dry blood spot (DBS) based test for SARS-CoV-2 IgG amid the COVID-19 pandemic.
Using the Waltham, Mass.-based company’s GSP/DELFIA platform that processes up to 5,000 samples per day, the finger-prick sample system allows for decentralized sample collection and high-throughput testing, according to a news release.
The DBS assay runs on the GSP analyzer system, which combines with the universal time-resolved fluorescence (TRF) of the DELFIA platform. The workflow associated with the system includes sample collection, punching, measurement, reagents and software to detect anti-SARS-CoV-2 IgG antibodies.
PerkinElmer said it is marketing the product as a CE-IVD test with plans to apply for FDA emergency use authorization (EUA).
“Dried blood spot samples have been used in large scale population screening programs for decades and can help alleviate the costs and logistical constraints associated with collecting, transporting and processing venous blood for SARS-CoV-2 antibody testing,” PerkinElmer VP & GM of diagnostics Masoud Toloue said in the release. “This CE-IVD marked assay enables decentralized collection, a much-needed tool in COVID-19 testing.”